147 related articles for article (PubMed ID: 7915964)
1. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.
Prat J; Oliva E; Lerma E; Vaquero M; Matías-Guiu X
Cancer; 1994 Sep; 74(6):1778-83. PubMed ID: 7915964
[TBL] [Abstract][Full Text] [Related]
2. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N]
Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
7. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
9. Study of c-erbB-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma.
Nakae S; Shimada E; Urakawa T
J Surg Oncol; 1993 Dec; 54(4):246-51. PubMed ID: 7902886
[TBL] [Abstract][Full Text] [Related]
10. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma.
King SA; Adas AA; LiVolsi VA; Takahashi H; Behbakht K; McGovern P; Benjamin I; Rubin SC; Boyd J
Cancer; 1995 Jun; 75(11):2700-5. PubMed ID: 7743473
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status.
Wang D; Konishi I; Koshiyama M; Mandai M; Nanbu Y; Ishikawa Y; Mori T; Fujii S
Cancer; 1993 Nov; 72(9):2628-37. PubMed ID: 8104681
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.
Lipponen P; Eskelinen M
Br J Cancer; 1994 Jun; 69(6):1120-5. PubMed ID: 7911031
[TBL] [Abstract][Full Text] [Related]
13. Lymphoepithelioma-like carcinoma of the uterine cervix with c-erbB-2, p53 oncoprotein expression and DNA quantification.
Walsh CB; Kay E; Prendiville W; Turner M; Leader M
Histopathology; 1993 Dec; 23(6):592-3. PubMed ID: 7906245
[No Abstract] [Full Text] [Related]
14. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer.
Lukes AS; Kohler MF; Pieper CF; Kerns BJ; Bentley R; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC; Berchuck A
Cancer; 1994 May; 73(9):2380-5. PubMed ID: 7909491
[TBL] [Abstract][Full Text] [Related]
15. p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections.
Nielsen AL; Nyholm HC
Am J Clin Pathol; 1994 Jul; 102(1):76-9. PubMed ID: 7913577
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.
Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S
Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116
[TBL] [Abstract][Full Text] [Related]
17. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
18. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
Nagai N; Oshita T; Fujii T; Kioka H; Katsube Y; Ohama K
Oncol Rep; 2000; 7(3):551-9. PubMed ID: 10767367
[TBL] [Abstract][Full Text] [Related]
19. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
20. Uterine papillary serous carcinoma evolves via a p53-driven pathway.
Moll UM; Chalas E; Auguste M; Meaney D; Chumas J
Hum Pathol; 1996 Dec; 27(12):1295-300. PubMed ID: 8958301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
